Peter Alan Chambre Acquires Immatics N.V. Shares

Peter Alan Chambre recently acquired 48,000 shares of Immatics N.V. (NasdaqCM: IMTX) on June 16, 2026. This insider purchase did not disclose a transaction value, as the shares were acquired without a specified price.

Insider Buying and Selling at Immatics N.V.

Chambre's recent purchase on June 16, 2026, was accompanied by similar transactions from other insiders, including Mathias Hothum, Michael Atieh, Heather Mason, and Paul Rutherford Carter, each acquiring 48,000 shares. These transactions were not part of a pre-planned trading program.

Other Institutional Activity in Immatics N.V.

Among other institutional investors, RTW Investments, LP significantly increased its stake by adding 1,435,986 shares, bringing its total to 12,869,340 shares valued at approximately $126.6 million. Meanwhile, T. Rowe Price Investment Management, Inc. also boosted its position by 193,006 shares, ending with 21,652,162 shares worth about $213.1 million. On the other hand, Baker Bros. Advisors LP reduced its holdings by 1,177,401 shares, leaving it with 10,916,693 shares valued at $107.4 million.

Immatics N.V. Stock Up 0.7%

Shares of Immatics N.V. are currently trading near $9.52. The company has a market capitalization of approximately $1.3 billion. Although it currently lacks a meaningful P/E ratio due to unprofitability, Immatics shows a forward P/E of -5.03. The stock's 52-week range is between $5.05 and $12.41, with a 50-day moving average of $10.73 and a 200-day moving average of $9.78. Immatics' financial health is supported by a strong current ratio of 8.78 and a quick ratio of 8.30, with a debt-to-equity ratio of 3.31.

Recent Earnings

Immatics reported revenue of $37.3 million, although it faced a revenue decline of 59%. The company has not achieved profitability, reflected in a return on equity of -43.2%. The next earnings report is anticipated on August 13, 2026.

Analysts Set New Price Targets

On May 19, 2026, Chardan Capital maintained its 'buy' rating on Immatics with a price target of $25. Jefferies also assumed coverage with a 'buy' rating and an $18 target on March 16, 2026. The consensus among eight analysts is a strong buy, with a mean price target of $18.78.

About Immatics N.V.

Immatics N.V. is a clinical-stage biopharmaceutical company based in Tübingen, Germany. It focuses on developing T cell redirecting immunotherapies for cancer treatment, particularly targeting solid tumors. The company's pipeline includes several promising therapies, such as Anzu-cel (IMA203) and IMA203CD8, which are in various clinical trial phases. Immatics collaborates with notable institutions like MD Anderson Cancer Center and Celgene Corporation to advance its cancer treatment technologies.

Bottom Line

Peter Alan Chambre's acquisition of Immatics N.V. shares highlights ongoing insider interest in the company. Investors often track such transactions for potential insights into company prospects. As a clinical-stage biotech firm, Immatics presents both opportunities and risks, reflected in its analyst ratings and financial metrics. Keep in mind, insider purchases are disclosed after the fact and may not indicate future stock performance.